SecBot SecBot
8-K ·Filed Nov 9, 2026

INM

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7d 18h ago SEC0001193125-26-452706
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor Phase 1 data for MT-001 expected mid-2027 and regulatory filing for MT-002 in Q1 2027. The $490M financing provides a multi-year runway, reducing near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

INM drug pipeline →

MT-001

● Neutral Named in this 8-K
Impact
Phase
Preclinical (IND-enabling)
Time to market
Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
Next catalyst
None dated

What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$16.00
T+0 close · Nov 9, 2026 · via day close
Latest settled
+16.25%
T+5 · $18.60
Vs SPY
+17.94%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $16.00entry
  2. T+1 · 7d ago −23.75%α −23.38% · $12.20
  3. T+5 · 20h ago +16.25%α +17.94% · $18.60
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mentari Therapeutics (formerly InMed Pharmaceuticals) completed its merger with Mentari Therapeutics and closed $490M in private financings. The combined company trades under MTRI and has a clinical pipeline targeting migraine prevention with two lead candidates, MT-001 and MT-002.

Key Facts

  • Merger between InMed Pharmaceuticals and Mentari Therapeutics closed on November 9, 2026
  • Combined company renamed Mentari Therapeutics, Inc., trading under ticker MTRI on Nasdaq
  • Private placement financings closed with gross proceeds of approximately $490 million
  • Proceeds include conversion of $50.0 million of previously issued convertible notes plus accrued interest
  • Approximately 58.3 million shares of common stock and common stock equivalents outstanding post-transaction
  • MT-001 (anti-PACAP monoclonal antibody) in Phase 1 clinical trial with initial data expected mid-2027
  • MT-002 (bispecific anti-PACAP/anti-CGRP antibody) on track for regulatory filing Q1 2027 with data expected year-end 2027
  • Todd Shegog appointed to Board of Directors as Chair of Audit Committee

Financial Impact

Combined company raised $490M in gross proceeds from private placements, providing cash runway into 2029. Post-merger share count approximately 58.3 million shares and equivalents.

cash runwaydilutionshare count

Risk Factors

  • Clinical-stage company with no approved products; MT-001 and MT-002 are investigational
  • Phase 1 data for MT-001 not expected until mid-2027; no near-term revenue catalysts
  • Significant dilution from the reverse stock split and private placement financings
  • Competition from existing anti-CGRP therapies for migraine

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-452706
Document: d183007dex991.htm0001193125-26-452706
Document: 0001193125-26-452706-index-headers.html0001193125-26-452706
Document: 0001193125-26-452706-index.html0001193125-26-452706
Document: 0001193125-26-452706.txt0001193125-26-452706

Track record

22 reports on INM

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $16.00 Now $19.87 +24.19% settles Dec 8
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
  5. Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
  6. Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
  7. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
  8. Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
  9. Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
  10. Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026